Industry News
Excerpt from the Press Release: Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6,…
Read More
-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1 monotherapy Excerpt from the Press Release: RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients…
Read More
New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering novel mechanism of action of AU-007, Aulos’ computationally designed antibody in the IL-2 class Initial anti-tumor activity has been observed since the ASCO data cutoff date, with additional data anticipated by year-end as the Phase 1/2 trial continues to enroll…
Read More
Rejuva device & procedure reliably and successfully targets pancreas with Adeno Associated Virus (AAV), potentially enabling gene therapy to address pancreatic diseases for the first time Rejuva platform and genetic medicines offer potential for reversal of Type 2 Diabetes with a single point-in-time local administration of durable GLP-1-based genetic medicines Excerpt from the Press Release:…
Read More
Combination therapy led to nearly 19% weight loss at approximately 8 months Excerpt from the Press Release: NATICK, Mass.–(BUSINESS WIRE)–Allurion, a company dedicated to ending obesity, today announced results from a new study that will be presented at the European Congress on Obesity exploring the use of a GLP-1 weight-loss medication with the Allurion Gastric…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Rejuvenate Bio, today announced new data for its gene therapy RJB-01 from a pilot study in canines with myxomatous mitral valve disease (MMVD), at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 16-20, 2023, in Los Angeles, California. RJB-01, expresses…
Read More
Oral presentation highlights EPI-321 effects on multiple clinically relevant markers – Excerpt from the Press Release: – Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today presented promising preclinical data supporting development of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The data were shared in…
Read More
Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases Excerpt from the Press Release: NEWARK, Calif., May 12, 2023 /PRNewswire/ — Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on…
Read More
Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel in psoriasis expected in 2024 Reviva has filed composition of matter patent for brilaroxazine-lipogel and a separate patent for use in the treatment of psoriasis Excerpt from the Press Release: CUPERTINO, Calif., May 11, 2023…
Read More
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Excerpt from the Press Release: Carlsbad, CA, May 11, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced…
Read More